Nextech Invest
Thilo Schroeder, Ph.D. has a passion for precision medicines in cancer with a focus on identifying first and best-in-class targeted therapies regardless of drug modality. Since 2012, Thilo has helped grow and shape Nextech as a leading oncology focused venture firm.
Thilo is a board member of Revolution Medicines (NASDAQ: RVMD), PMV Pharma (NASDAQ: PVMP), Circle Pharma, Silverback Therapeutics (NASDAQ: SBTX), MOMA Therapeutics. Past board seats include Blueprint Medicines (NASDAQ: BPMC), Peloton Therapeutics (acquired by Merck) and IDEAYA Biosciences (NASDAQ: IDYA). Thilo is a past board observer of BlackDiamond Therapeutics (NASDAQ: BDTX).
Thilo began his biotech career at the pioneering cancer immunology company Micromet (acquired by Amgen) while studying at Ecole Supérieure de Biotechnologie de Strasbourg, conducted research at the University of Sydney and obtained his Ph.D. from the University of Zurich, focused on protein engineering in the development of Designed Ankyrin Repeat Proteins (DARPins), a technology developed by Molecular Partners (SWX:MOLN).
This person is not in any offices
Nextech Invest
Nextech is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. They focus almost exclusively on oncology therapeutics, and on helping to drive value creation for their portfolio companies. They invest in the most promising drug discovery companies with the potential to create multiple medicines. Their portfolio is focused throughout the US and Europe with investments from company inceptions to crossover rounds.